Biotech News

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

Pliant Therapeutics (PLRX)Pliant TherapeuticsCompany update

Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.

Related news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

Stock data

Close
0.62 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States